Search by Drug Name or NDC

    NDC 49281-0574-15 BEYFORTUS 100 mg/mL Details

    BEYFORTUS 100 mg/mL

    BEYFORTUS is a INTRAMUSCULAR INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sanofi Pasteur Inc.. The primary component is NIRSEVIMAB.

    Product Information

    NDC 49281-0574
    Product ID 49281-574_68042e47-6495-4b99-a244-3360c4e5ce06
    Associated GPIs
    GCN Sequence Number 085071
    GCN Sequence Number Description nirsevimab-alip SYRINGE 100 MG/ML INTRAMUSC
    HIC3 W5D
    HIC3 Description ANTIVIRAL MONOCLONAL ANTIBODIES
    GCN 54467
    HICL Sequence Number 049077
    HICL Sequence Number Description NIRSEVIMAB-ALIP
    Brand/Generic Brand
    Proprietary Name BEYFORTUS
    Proprietary Name Suffix n/a
    Non-Proprietary Name nirsevimab
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION
    Route INTRAMUSCULAR
    Active Ingredient Strength 100
    Active Ingredient Units mg/mL
    Substance Name NIRSEVIMAB
    Labeler Name Sanofi Pasteur Inc.
    Pharmaceutical Class Fusion Protein Inhibitors [MoA], Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761328
    Listing Certified Through 2024-12-31

    Package

    NDC 49281-0574-15 (49281057415)

    NDC Package Code 49281-574-15
    Billing NDC 49281057415
    Package 5 SYRINGE in 1 CARTON (49281-574-15) / .5 mL in 1 SYRINGE
    Marketing Start Date 2023-07-18
    NDC Exclude Flag N
    Pricing Information N/A